Introducing Memantine HCl Tablets by PharmAlliance International Labs

Welcome to PharmAlliance International Labs, where we are committed to pioneering advancements in healthcare through innovative and superior-quality pharmaceutical products. Our Memantine HCl Tablets epitomize our dedication to enhancing the well-being of individuals grappling with neurological disorders.

Drug Classification:

Memantine is classified as an N-methyl-D-aspartate (NMDA) receptor antagonist, a distinguished class of medications renowned for their efficacy in modulating glutamate activity, a pivotal neurotransmitter implicated in memory and learning processes. By antagonizing NMDA receptors, memantine effectively regulates neural signaling, mitigates excitotoxicity, and presents a valuable therapeutic avenue for neurodegenerative conditions.

Formulations:

Memantine HCl Tablets:

• • Strength: Each tablet contains 10mg of memantine hydrochloride.
  • Product Form: Convenient oral tablets.
  • Packing Specifications: Packaged with 30 tablets for patient convenience.

Indications:

Memantine HCl Tablets are indicated for the treatment of moderate to severe Alzheimer’s disease and other forms of dementia. Prescribed to alleviate cognitive decline symptoms such as memory loss, confusion, and behavioral disturbances, memantine offers symptomatic relief while decelerating the progression of cognitive impairment in Alzheimer’s patients.

Usage:

Administer Memantine HCl Tablets orally once daily, with or without food, as directed by a healthcare professional. Strict adherence to prescribed dosages and treatment regimens is paramount for optimal therapeutic outcomes. Dosage adjustments, if necessary, should be conducted under healthcare provider supervision based on individual response and tolerability.

Dosage:

The recommended starting dosage for Alzheimer’s disease is 5mg once daily, with subsequent titration to a target maintenance dosage of 10mg twice daily (20mg/day). Patients with moderate to severe renal impairment require dosage adjustment, with a maximum recommended dosage of 5mg once daily.

Pharmacokinetics:

Memantine exhibits rapid absorption post-oral administration, achieving peak plasma concentrations within 3 to 7 hours. Metabolized minimally via hepatic pathways, primarily CYP2D6 and CYP3A4, memantine is predominantly excreted unchanged in urine, boasting a terminal elimination half-life of approximately 60 to 80 hours.

Pharmacodynamics:

The pharmacological action of memantine revolves around selective NMDA receptor blockade, effectively curbing glutamate-mediated excitotoxicity. By restoring synaptic function and neuronal integrity, memantine engenders improved cognitive function and symptom management in Alzheimer’s disease patients.

Side Effects:

Common side effects associated with Memantine HCl Tablets encompass dizziness, headache, constipation, and confusion. Some individuals may experience fatigue, agitation, and hallucinations, particularly at higher dosages. Rigorous monitoring for cognitive decline or behavioral changes is essential, with adverse effects promptly reported to healthcare providers.

Place your trust in the efficacy and safety of Memantine HCl Tablets from PharmAlliance International Labs. We remain steadfast in our commitment to supporting individuals battling Alzheimer’s disease and various forms of dementia, equipping them with the treatment necessary to sustain cognitive function and elevate their quality of life. For additional information, please visit our website or consult with your healthcare provider.